November 16, 2022 | Advocacy, Funding, Treatments
At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the […]
July 26, 2022 | Life with MS, Progressive, Research
Multiple Sclerosis NZ is currently in the process of providing information to Pharmac regarding the high unmet need of those with Secondary Progressive MS. A new treatment, Siponimod (Mayzent), is currently under review and due to be assessed by PTAC […]
November 3, 2021 | Education, Event, Progressive, Uncategorised
The 37th Congress of the European Committee for Treatment and Research in MS (ECTRIMS) was held online recently. The scientific programme comprised well-known session formats such as Scientific Sessions, Hot Topics and Meet the Experts, as well as live discussions […]